echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Genting Xinyao Gosartuzumab for the treatment of mTNBC listing application accepted in Taiwan, China

    Genting Xinyao Gosartuzumab for the treatment of mTNBC listing application accepted in Taiwan, China

    • Last Update: 2022-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 4, Genting Shinya announced that the Food and Drug Administration of Taiwan, China has accepted the New Drug Marketing Application (NDA) of Sacituzumab Govitecan for the treatment of unresectable locally advanced or metastatic adult patients.


    The English trade name of Gosartuzumab is Trodelvy®.


    In November 2021, Genting Xinyao announced the key results of the phase 2b EVER-132-001 study of gosartuzumab, which reached its primary endpoint with an objective response rate (ORR) of 38.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.